SCHEMBL670902

SCHEMBL670902

NC1CCC(C(F)(F)F)CC1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670903 1.00 NOS3 (0.34) NOS3NOS1NOS2
SCHEMBL3133240 1.00 NOS3 (0.34) NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL1671816 0.97 NOS3 (0.33) NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL1671814 0.97 NOS3 (0.33) NOS3NOS1NOS2
SCHEMBL18060 0.83
SCHEMBL1035408 0.83 NOS3 (0.36) NOS3NOS1NOS2
SCHEMBL18682821 0.82 NOS3 (0.32) NOS3NOS1NOS2
SCHEMBL30398851 0.82 NOS3 (0.32) NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL30398689 0.80 NOS3 (0.31) NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL30399590 0.80 NOS3 (0.31) NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115304758-B Sulfur-containing polyester based on orcinol derivative, preparation and application 深圳万知达技术转移中心有限公司 2024-03-01 CN claimed
US-20230337447-A1 QUANTUM DOT LIGHT EMITTING DEVICE AND MANUFACTURING METHOD THEREFOR, AND DISPLAY DEVICE Beijing Boe Technology Development Co., Ltd. (CN) 2023-10-19 US claimed
CN-115394930-A Light-emitting device, preparation method thereof and display device 北京京东方技术开发有限公司 2022-11-25 CN claimed
CN-115304758-A Sulfur-containing polyester based on orcinol derivatives, preparation and application 武汉科技大学 2022-11-08 CN claimed
EP-4021441-A1 MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF Trustees of Dartmouth College (US) 2022-07-06 EP claimed
WO-2022062718-A1 QUANTUM DOT LIGHT EMITTING DEVICE AND MANUFACTURING METHOD THEREFOR, AND DISPLAY DEVICE 京东方科技集团股份有限公司 2022-03-31 WO claimed
WO-2021042046-A1 MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF TRUSTEES OF DARTMOUTH COLLEGE (US) 2021-03-04 WO claimed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US claimed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US claimed
WO-2010034796-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO claimed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO claimed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 US disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP disclosed
EP-0048376-B1 PROCESS FOR THE PREPARATION OF N-SUBSTITUTED DIARYL IMIDODICARBOXYLATES BAYER AG (DE) 1984-02-15 EP disclosed
EP-0048377-B1 PROCESS FOR THE PREPARATION OF N-SUBSTITUTED DIARYL IMIDODICARBOXYLATES BAYER AG (DE) 1983-10-19 EP disclosed
US-4348331-A FROM THE HYDROCHLORIDE OF A PRIMARY AMINE AND AN ARYL ESTER HALIDE BAYER AKTIENGESELLSCHAFT (DE) 1982-09-07 US disclosed
EP-0048376-A1 Process for the preparation of N-substituted diaryl imidodicarboxylates BAYER AG (DE) 1982-03-31 EP disclosed
US-4194008-A INSECTICIDE, FUNGICIDE, MITICIDE, PARASITICIDES BAYER AKTIENGESELLSCHAFT (DE) 1980-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027096-A1 PHD INHIBITORS HIF1AN, HIF1A, EGLN1 NOS3 962/4885NOS1 406/4885NOS2 440/4885
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 NOS3 187/4885NOS1 432/4885NOS2 294/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B NOS3 4073/4885NOS1 4160/4885NOS2 4484/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD NOS3 2682/4885NOS1 2922/4885NOS2 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.